1. Aims: What matters to the individual about their condition(s)?
Review diagnoses and consider:
- Therapeutic objectives of drug therapy
- Management of existing health problems
- Prevention of future health issues, including lifestyle advice
Ask person to complete PROMs (Questions to answer before medicines review) before their review
Person specific issues to address
- Reduce avoidable harms from street drugs, OTC medicines and alcohol use
- Manage pain from previous assault-consider trauma informed approach
2. Need: Identify essential drug therapy
Identify essential drugs (not to be stopped without specialist advice)
- Drugs that have essential replacement functions (e.g. levothyroxine)
- Drugs to prevent rapid symptomatic decline (e.g. drugs for Parkinson’s disease, heart failure)
Person specific issues to address
- No drugs considered essential
- Although not essential, street benzodiazepines, alcohol and OTC co-codamol should not be stopped suddenly – see below for risks. He requires support to safely reduce his use. Referral to specialist service and/or third sector partner
3. Does the individual take unnecessary drug therapy?
Identify and review the continued need for drugs
- what is medication for?
- with temporary indications
- with higher than usual maintenance doses
- with limited benefit/evidence for use
- with limited benefit in the person under review (see Drug efficacy & applicability (NNT) table)
Person specific issues to address
- Having checked his understanding of the current risks, he is offered further harm reduction advice in relation to his benzodiazepine, alcohol and co-codamol use
4. Effectiveness: Are therapeutic objectives being achieved?
Identify the need for adding/intensifying drug therapy to achieve therapeutic objectives
- to achieve symptom control
- to achieve biochemical/clinical targets
- to prevent disease progression/exacerbation
- is there a more appropriate medication to achieve goals?
Person specific issues to address
- Work with specialist service to develop a shared care plan for him which may include prescribing for alcohol detox, relapse prevention and appropriate vitamins, diazepam detox and opioid substitution therapy (OST)
- Pain to be discussed in greater detail at follow up appointment, explaining the difference between acute and chronic pain
5. Safety: Does the individual have or is at risk of ADR/ side effects? Does the patient know what to do if they’re ill?
Identify individual safety risks by checking for
Identify adverse drug effects by checking for
- specific symptoms/laboratory markers (e.g. hypokalaemia)
- cumulative adverse drug effects (see ADR table)
- drugs used to treat side effects caused by other drugs
Medication Sick Day guidance
- Ensure discussion and clear information on which medicines to withhold at times of dehydrating illness
Person specific issues to address
- Discuss increased overdose risk with the combination of benzodiazepines, alcohol and opiate (co-codamol)
- Need for appropriate harm reduction strategies including dose reduction. Advice includes:
- avoid buying larger quantities of benzodiazepines to limit the risk of an overdose
- splitting doses throughout the day to avoid discontinuation/withdrawal symptoms
- keep a note of how much and how often he takes
- Opioids: supply take home naloxone kit
- Benzodiazepines: discuss risk associated with street supply - purity and strength are unknown
- Alcohol: discuss risk associated with alcohol consumption.AUDIT score of 20 indicates specialist referral required
- Paracetamol: discuss the possible effects on his liver from co-codamol use above recommended doses for a prolonged period of time
- He must not drive if he is unfit to do so, because he has taken medication or street drugs
6. Sustainability: Is drug therapy cost-effective and environmentally sustainable?
Identify unnecessarily costly drug therapy by
- considering more cost-effective alternatives, formulary choices, safety, convenience
Consider the environmental impact of
- Inhaler use
- Single use plastics
- Medicines waste
- Water pollution
Person specific issues to address
7. Person-centredness: Is the person willing and able to take drug therapy as intended?
Does the person understand the outcomes of the review?
Ensure drug therapy changes are tailored to individual’s preferences. Consider
- is the medication in a form they can take?
- is the dosing schedule convenient?
- what assistance is needed?
- are they able to take medicines as intended?
Agree and communicate plan
- discuss and agree with the individual/carer/welfare proxy therapeutic objectives and treatment priorities
- include lifestyle and holistic management goals
- inform relevant health and social care providers of changes in treatments across the transitions of care
Ask person to complete PROMs (Questions to answer after medicines review) after their review
Agreed plan
- Gradual reduction of street benzodiazepines, OTC co-codamol, alcohol intake whilst considering specialist input
- Referral offered to specialist drug and alcohol service, discussed and encouraged, but reluctant to engage at this time. He agrees to attend a local third sector drop-in
- Naloxone trained and has a kit. Advise where friends and family can obtain a kit
- Discuss worsening symptoms and possible increasing self-harm/suicide risk. Give out of hours telephone numbers, e.g. Breathing Space, Samaritans, NHS 24
- Written information provided to support discussions
- Follow-up appointment in seven days’ time for ongoing pain management, and check if attended third sector drop-in. Discuss specialist referral again